213015-69-1

Basic information

• Product Name: Glycine, N-[(4-fluorophenyl)sulfonyl]-, 1,1-dimethylethyl ester
• CAS NO: 213015-69-1
• Molecular Formula: C12H16FNO4S
• Molecular Weight: 289.328
• Mol File: 213015-69-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Glycine, N-[(4-fluorophenyl)sulfonyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-[(4-fluorophenyl)sulfonyl]-, 1,1-dimethylethyl ester(213015-69-1)
• EPA Substance Registry System: Glycine, N-[(4-fluorophenyl)sulfonyl]-, 1,1-dimethylethyl ester(213015-69-1)

Safety Data

• Hazardous Substances Data: 213015-69-1(Hazardous Substances Data)

Upstream product

• 349-88-2 4-Fluorobenzenesulfonyl chloride 
• 27532-96-3 glycine tert-butyl ester hydrochloride 
• 13029-71-5 2-(4-fluorophenylsulfonamido)acetic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 

Downstream Products

• 245365-02-0 N-benzyloxy-2-[(4-chloro-benzyl)-(4-fluoro-benzenesulfonyl)-amino]-acetamide 
• 245365-05-3 N-benzyloxy-2-[(4-fluoro-benzenesulfonyl)-(4-methyl-benzyl)-amino]-acetamide 
• 245364-99-2 2-[benzyl-(4-fluoro-benzenesulfonyl)-amino]-N-benzyloxy-acetamide 
• 276695-39-7 N-benzyl-N-[(4-fluorophenyl)sulfonyl]glycine 
• 245364-73-2 [(4-chloro-benzyl)-(4-fluoro-benzenesulfonyl)-amino]-acetic acid tert-butyl ester 
• 245364-76-5 [(4-fluoro-benzenesulfonyl)-(4-methyl-benzyl)-amino]-acetic acid tert-butyl ester 
• 2361659-61-0 C₃₃H₂₉F₆N₃O₅S 

Relevant articles and documents

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required. Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clinical studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC. We developed an inhibitor of HDACs, AES-135, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochemical assays. In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-associated fibroblasts and has excellent pharmacokinetic properties in vivo. In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclinical testing.

Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates

The SAR of a series of potent sulfonamide hydroxamate TACE inhibitors, all bearing a butynyloxy P1′ group, was explored. In particular, compound 5j has excellent in vitro potency against isolated TACE enzyme and in cells, good selectivity over MMP-1 and MMP-9, and oral activity in an in vivo model of TNF-α production and a collagen-induced arthritis model.